Sonoma Pharmaceuticals (NASDAQ:SNOA) shared it received a record number of quarterly prescriptions for their dermatology products.
As quoted in the press release:
The number of prescriptions filled during the June 2017 quarter was 17,180, up 24% over the March 2017 quarter of 13,795, and up 46% over the June 2016 quarter of 11,787.
For the June 2017 quarter the following product lines experienced double-digit growth over the March 2017 quarter:
- Alevicyn for atopic dermatitis up 26%
- Celacyn for scar treatment up 31%
- Mondoxyne for severe acne up 31%
- Sebuderm for seborrheic dermatitis up 42% (recently launched)
In the fall of 2014, Sonoma announced a new strategic direction for the company, crafted by the company’s new board and management team, which focused on launching products into the U.S. dermatology market with the company’s own direct sales force. This initiative has been led by dermatology veterans, launching five product lines and growing this business from zero to over 17,000 prescriptions filled in the June 2017 quarter.